Osteogenesis imperfecta - managing brittle bones

Article Abstract:

Pamidronate may be the first effective drug therapy for osteogenesis imperfecta, a genetic disorder that causes brittle bones. Patients with the condition have frequent fractures, bowing of the long bones, spinal deformities, and other connective tissue abnormalities. Physical therapy to increase strength, conditioning, and joint stability can reduce the risk of fracture and increase patient independence. Pamidronate is a biphosphonate drug which suppresses bone loss and increases bone mineral density. Research in children indicates it may significantly reduce the risk of fracture.

Health aspects, Editorial

---

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

Article Abstract:

Pamidronate appears to increase bone mineral density, decrease the rate of bone fracture, and decrease bone pain in children with osteogenesis imperfecta. This genetic disorder causes brittle bones, progressive bone deformity, and pain. Researchers treated 30 children with pamidronate, which reduces bone loss, every 4-6 months for 1-5 years. Treated children had lower excretion of calcium in the urine, 42% annual increases in bone density, 1.7 fewer fractures each year, and less pain and fatigue.

Evaluation

---

Do bisphosphonates make children's bones better or brittle?

Article Abstract:

Doctors should be very cautious when prescribing a group of drugs called bisphosphonates for children with certain types of bone disease. These drugs are most commonly used to treat osteoporosis in postmenopausal women. A case report published in 2003 revealed that long-term bisphosphonate therapy in children can cause their bones to become brittle. This could increase the risk of bone fractures.

Children, Care and treatment, Complications and side effects, Bone diseases, Diphosphonates, Children in television

Similar abstracts:

• Abstracts: Web technology: coming soon to a hospital near you. New Jersey hospital makes babies Web celebrities
• Abstracts: Management of myeloma with bisphosphonates. Bisphosphonates in the treatment of bone diseases. Multiple myeloma
• Abstracts: Dilemma seen in conflict of economics, medical needs. Increasing visibility: new President Scott sees Alliance as a cohesive force for medicine
• Abstracts: Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
• Abstracts: Antenatal thyrotropin-releasing hormone to prevent lung disease in preterm infants. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.